Australian researchers led by Cathy Jensen looked into whether SNPs associated with risk of multiple sclerosis also affect the severity of the disease. To do so, they genotyped seven SNPs in more than a thousand people with MS and correlated that with clinical outcome measures such as age of onset, MS severity score, and the time interval between first demyelinating event and first relapse. The researchers found no association between those clinical outcomes and the SNPs under study.